{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:52:49Z","timestamp":1793641969437,"version":"4.5.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40265-022-01793-1","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T23:32:41Z","timestamp":1668036761000},"page":"1613-1619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Teclistamab: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"issue":"10301","key":"1793_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"key":"1793_CR2","unstructured":"Johnson & Johnson. Janssen marks first approval worldwide for TECVAYLI\u00ae (teclistamab) with EC authorisation of first-in-class bispecific antibody for the treatment of patients with multiple myeloma [media release]. 24 Aug 2022. https:\/\/www.jnj.com."},{"key":"1793_CR3","unstructured":"Janssen Biologics B.V. TECVAYLI: EU summary of product characteristics. 2022. https:\/\/ec.europa.eu. Accessed 29 Sep 2022."},{"key":"1793_CR4","unstructured":"U.S. Food & Drugs Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma [media release]. 26 Oct 2022. https:\/\/www.fda.gov"},{"key":"1793_CR5","unstructured":"Johnson & Johnson. Pharmaceutical pipeline. 2022. https:\/\/www.investor.jnj.com. Accessed 29 Sep 2022."},{"key":"1793_CR6","unstructured":"Genmab AS. Genmab enters broad collaboration with Janssen Biotech, Inc. for DuoBody platform [media release]. 12 Jul 2012. https:\/\/www.genmab.com."},{"key":"1793_CR7","unstructured":"Genmab AS. Genmab announces expansion of DuoBody platform collaboration with Janssen Biotech, Inc. [media release]. 4 Dec 2013. https:\/\/www.genmab.com."},{"key":"1793_CR8","unstructured":"Ligand Pharmaceuticals. Ligand announces licensing partner Janssen has filed an IND for an antibody discovered using the OmniAb\u00ae technology [media release]. 28 Mar 2017. https:\/\/investor.ligand.com\/press-releases."},{"key":"1793_CR9","unstructured":"SpringWorks Therapeutics, Inc. SpringWorks Therapeutics announces clinical collaboration with Janssen to evaluate nirogacestat in combination with teclistamab in patients with relapsed or refractory multiple myeloma [media release]. 14 Sep 2020. http:\/\/www.springworkstx.com."},{"issue":"19","key":"1793_CR10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585\u201397.","journal-title":"Blood"},{"key":"1793_CR11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007625","author":"S Girgis","year":"2022","unstructured":"Girgis S, Lin SXW, Pillarisetti K, et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2022. https:\/\/doi.org\/10.1182\/bloodadvances.2022007625.","journal-title":"Blood Adv"},{"issue":"4","key":"1793_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11523-022-00893-y","volume":"17","author":"S Girgis","year":"2022","unstructured":"Girgis S, Lin SXW, Pillarisetti K, et al. Translational modeling predicts efficacious therapeutic dosing range of teclistamab for multiple myeloma. Target Oncol. 2022;17(4):433\u20139.","journal-title":"Target Oncol"},{"issue":"6","key":"1793_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. NEJM. 2022;387(6):495\u2013505.","journal-title":"NEJM"},{"key":"1793_CR14","doi-asserted-by":"crossref","unstructured":"Martinez-Lopez J, Moreau P, Usmani SZ, et al. Updated efficacy and safety results of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma from MajesTEC-1 [abstract no. P921]. HemaSphere. 2022;6(S3):811\u20132.","DOI":"10.1097\/01.HS9.0000846552.63695.9d"},{"key":"1793_CR15","doi-asserted-by":"crossref","unstructured":"Popat R, Moreau P, Usmani SZ, et al. Health-related quality of life with teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma from MajesTEC-1 [abstract no. P922]. HemaSphere. 2022;6 (S3):812\u20133.","DOI":"10.1097\/01.HS9.0000846556.04927.df"},{"key":"1793_CR16","doi-asserted-by":"crossref","unstructured":"Rodriguez Otero P, D'Souza A, Reece D, et al. Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma: updated phase 1b results [abstract no. S188]. HemaSphere. 2022;6(S3):89\u201390.","DOI":"10.1097\/01.HS9.0000843644.02496.66"},{"key":"1793_CR17","doi-asserted-by":"crossref","unstructured":"Krishnan AY, Nooka AK, Chari A, et al. Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed\/refractory multiple myeloma (RRMM) [abstract no. 8036]. J Clin Oncol. 2022;40(16 Suppl):8036.","DOI":"10.1200\/JCO.2022.40.16_suppl.8036"},{"key":"1793_CR18","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ, Moreau P, Delforge M, et al. Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM) [abstract no. 8016]. J Clin Oncol. 2022;40(16 Suppl):8016.","DOI":"10.1200\/JCO.2022.40.16_suppl.8016"},{"key":"1793_CR19","doi-asserted-by":"crossref","unstructured":"Delforge M, Moreau P, Einsele H, et al. Health-related quality of life (HRQoL) in patients with relapsed\/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study [abstract no. 8030]. J Clin Oncol. 2022;40(16 Suppl):8030.","DOI":"10.1200\/JCO.2022.40.16_suppl.8030"},{"key":"1793_CR20","doi-asserted-by":"crossref","unstructured":"Mateos MV, Bahlis NJ, Costa LJ, et al. MajesTEC-3: randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed\/refractory multiple myeloma [abstract no. TPS8072]. J Clin Oncol. 2022;40(16 Suppl):TPS8072.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01793-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:16:32Z","timestamp":1744701392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01793-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01793-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"10 November 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}